As per the American Skin Association, Melanoma is a life-threatening Metastatic tumor that originates in cells called melanocytes, which are pigment-producing cells. The majority of melanomas are black or brown. However, some Melanomas are skin-colored, pink, red, purple, blue, or white. Melanoma begins on the skin where it is easy to see and treat. However, it can grow into the skin, reaching the blood vessels and lymphatics, and can spread within the body to various organs when it can be fatal. If it is recognized and treated early, the chances of recovery are very good. But if it is not found early, it can grow deeper into the skin and spread to other parts of the body. Once Melanoma spreads beyond the skin to other parts of the body, it becomes hard to treat and can be fatal.
Several therapies have been approved by the US Food and Drug Administration (FDA) over the past years. Depending on the features of the tumor (location, stage, and genetic profile), the therapeutic options may be surgical resection, chemotherapy, radiotherapy, photodynamic therapy (PDT), immunotherapy, or targeted therapy.
Over the past decades, the knowledge of melanoma has improved dramatically, leading to discoveries that have been translated into therapeutic developments and prevention strategies. Genomic studies and clinical trials on individuals from different ethnicities are urgently needed to improve patient’s survival with melanoma subtypes that are more common in these populations.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/melanoma-market
The Melanoma Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Melanoma market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Melanoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Melanoma Market Key Facts
-
As per the National Cancer Institute, in 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to Melanoma are between the age group of 55 to 85 years.
-
According to Cancer.Net, if the melanoma has spread to other, distant parts of the body, the survival rate is lower, about 27%. Approximately 4% of cases are diagnosed at this stage.
-
According to the SEER estimates: In 2020, 100,350 new cases of Melanoma were observed. More than half of the new cases occur in patients 60+ years of age.
-
As per Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new melanoma skin cancer cases in the UK every year. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.
-
According to the American Cancer Society, Melanoma is more prominent in males than females.
Key Benefits of Melanoma Market Report
-
Melanoma market report provides an in-depth analysis of Melanoma Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Melanoma Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Melanoma current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Melanoma market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The Melanoma market size is anticipated to increase during the study period owing to the increase in the research and development programs related to Melanoma in recent years. The launch of emerging therapies will also boost market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Melanoma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Melanoma Epidemiology
The epidemiology section covers insights about the historical and current Melanoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Melanoma Epidemiology Segmentation
-
Incident cases of Melanoma
-
Type-specific cases Melanoma
-
Stage-specific incident Cases of Melanoma
-
Mutation-specific (BRAF, MEK) incident Cases of Melanoma
-
Age-specific incident Cases of Melanoma
Melanoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Melanoma market or expected to get launched in the market during the study period. The analysis covers Melanoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Melanoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Melanoma market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisition, and merger, licensing, patent details, and other information for Melanoma emerging therapies.
The treatment of Melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered an option in some instances.
The dynamic of the Melanoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world.
Melanoma Companies –
-
Aim ImmunoTech
-
Bristol Myers Squibb
-
Evelo Biosciences
-
Hemispherx Biopharma
-
Idera Pharmaceuticals
-
Immutep
-
Infinity Pharmaceuticals
-
Iovance Biotherapeutics
-
Nektar, Immutep
-
Oncolys BioPharma
-
Partner Therapeutics
-
Spring Bank Pharmaceuticals
And Many Others
The pipeline of Melanoma is quite robust with several products available in the developmental stage which are expected to launch during the forecast period.
Melanoma Therapies Covered in the report include:
-
EDP1503
-
IMO-2125
-
OBP 301
-
LN-144
-
Ampligen
-
IPI-549 +Nivolumab
-
Leukine in combination with ipilimumab and nivolumab
-
Eftilagimod alpha (LAG-3Ig or IMP321)
And Many More.
Table of Content
1. Key Insights
2. Executive Summary
3. Melanoma Competitive Intelligence Analysis
4. Melanoma Market Overview at a Glance
5. Melanoma Disease Background and Overview
6. Melanoma Patient Journey
7. Melanoma Epidemiology and Patient Population
8. Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Melanoma Unmet Needs
10. Key Endpoints of Melanoma Treatment
11. Melanoma Marketed Products
12. Melanoma Emerging Therapies
13. Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Melanoma Market Outlook (7 major markets)
16. Melanoma Access and Reimbursement Overview
17. KOL Views on the Melanoma Market.
18. Melanoma Market Drivers
19. Melanoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/melanoma-market
Latest Reports By DelveInsight
Melanoma Pipeline Insights
Melanoma Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Melanoma market.
Healthcare Blogs
Antibody-mediated Rejection Market
The rarity of Antibody-mediated Rejection has led to the absence of widely accepted treatment guidelines and FDA-approved therapies in the AMR market. To provide novel therapeutic options, some of the key companies such as CSL Behring, Hansa Biopharma, and Viela Bio are diligently working in the AMR market. To read more about the condition and its future market trends, visit: Key Pharma Companies In Antibody-mediated Rejection Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/